Business Context and Reporting Period
Recursion Pharmaceuticals, Inc. (RXRX) filed a Current Report on Form 8-K dated December 5, 2021. The filing announces the entry into a Material Definitive Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (collectively "Roche").
Key Financial Metrics and Agreement Terms
This filing details a strategic collaboration rather than periodic financial results. Key financial terms include:
- Upfront Payment: Roche is obligated to pay an upfront cash payment of $150 million upon the agreement's effectiveness.
- Phenomap Fees: Fees for creating and accepting Phenomaps could exceed $250 million for sixteen (16) accepted Phenomaps.
- External Use Option: If Roche exercises the option to use raw images outside the collaboration for all twelve (12) eligible Phenomaps, exercise fee payments could exceed $250 million.
- Milestone Potential: For each of up to forty (40) small molecule collaboration programs, successful development and commercialization could yield more than $300 million in research, development, commercialization, and net sales milestones, plus mid- to high-single digit tiered royalties.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company.
Material Changes and Strategic Outlook
The primary material change is the execution of the Collaboration and License Agreement. The partnership focuses on discovering and developing therapeutic small molecule programs in gastrointestinal cancer and key areas of neuroscience (the "Exclusive Fields").
- Collaboration Scope: Recursion will construct "Phenomaps" using imaging technology and machine-learning algorithms. Roche will collaborate to create multi-modal models.
- Program Options: Roche holds options to obtain exclusive licenses for collaboration programs. If Roche does not exercise options for certain programs, Recursion may independently develop them subject to consent and royalties.
- Exclusivity: Recursion is subject to exclusivity limitations regarding R&D activities in the Exclusive Fields during an agreed period, though pre-existing programs may continue.
Risks and Contingencies
The agreement includes standard termination provisions for material breach, insolvency, or Roche's convenience. Termination rights may apply to specific Exclusive Fields or the entire agreement. Future financial benefits are contingent upon the successful creation of Phenomaps, Roche's exercise of options, and the successful development and commercialization of therapeutic programs.
Investor Verification Checklist
- Confirm the effective date of the Collaboration Agreement to trigger the $150 million upfront payment.
- Monitor the number of Phenomaps created and accepted by Roche to assess potential fee revenue exceeding $250 million.
- Track Roche's exercise of the "External Use Option" for raw image data.
- Observe the selection and progression of the up to forty (40) small molecule collaboration programs toward milestone triggers.
- Review the press release (Exhibit 99.1) for additional management commentary on the strategic impact.